IV Drip Voluntarily Discontinues Social Media Posts for IV Hydration Therapy Following NAD Inquiry into Implied COVID-19 Messages

For Immediate Release
Contact: Abby Hills, Director of Communications, BBB National Programs

703.247.9330 / press@bbbnp.org 

New York, NY – October 28, 2020 – Following an inquiry by the National Advertising Division (NAD) of BBB National Programs, IV Drips Customized IV Hydration & Wellness (“IV Drips”) discontinued Instagram and Facebook social media posts which conveyed implied messages that its IV Hydration Therapy protects users against COVID-19.

Through its routine monitoring program, NAD challenged IV Drips’ Instagram post for IV Hydration Therapy, including an image with the text: 

  • “Protect Yourself & Your Loved Ones Boost Your Immune System,” 
  • Associated text stating “Trump Declares National Emergency Over COVID-19,” and
  • “Stay Safe. Stay Healthy. Strengthen your first line of defense with an immunity Drip.” 


NAD determined that the immunity boosting claims, together with references to COVID-19, reasonably convey the implied message that IV Hydration Therapy protects users against COVID-19. 

Health and safety concerns are a top priority for NAD’s monitoring efforts, with particular attention currently focused on advertising for COVID-19 treatments. NAD noted that the U.S. Centers for Disease Control and Prevention (CDC) and the FDA have both stated that there are no approved vaccines, drugs, or investigational products currently available to treat or prevent COVID-19. Both the FDA and FTC have issued dozens of warning letters to companies making claims about their products’ ability to treat or prevent COVID-19. 

NAD initially referred this case to the FDA and FTC for review because the advertiser did not respond to NAD’s request to provide substantiation for its claims. However, following the referral, IV Drips subsequently returned to NAD and agreed to participate in the advertising self-regulatory forum. 

In its response, the advertiser voluntarily discontinued the social media post in question, as well as additional social media posts on Facebook and Instagram which made similar implied claims that IV Hydration Therapy protects users against COVID-19 (e.g., “An Immunity Drip packed with Vitamin C is one of your best defenses against viruses! Along with washing your hands, keeping your immune system strong is essential for staying healthy during flu season” together with “#coronavirus”).

NAD appreciates the advertiser’s permanent discontinuance of the challenged advertisements and its commitment to avoid making any express or implied claims that promote its products’ abilities to protect consumers against COVID-19.

In its advertiser’s statement, IV Drips stated that “none of its [concierge IV hydration] services or products are intended to diagnose, treat, cure, or prevent any disease including COVID-19 and will not be advertised as such. One should always consult with their physician before beginning any IV hydration therapy program.”

###

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.    

Latest Decisions

Decision

National Advertising Division Finds Certain Verizon 5G Claims Supported; Recommends Modification or Discontinuation of Others

New York, NY – October 19, 2021 – In the first National Advertising Division (NAD) Complex Track case, NAD determined that certain comparative performance claims for Verizon Wireless, Inc.’s 5G wireless service are supported or are non-actionable puffery. 
Read the Decision
Decision

National Advertising Review Board Finds Certain AT&T Comparative Advertising Claims Supported; Recommends Discontinuation or Modification of Others

New York, NY – October 14, 2021 – The National Advertising Review Board (NARB) has determined that AT&T Services, Inc. properly supported certain comparative advertising claims for its fiber-optic internet service in one commercial and one internet video advertisement. However, it...

Read the Decision
Decision

ChromaDex, Inc. Discontinues Advertising Claims for Tru Niagen Dietary Supplement Following National Advertising Division Challenge

New York, NY – October 5, 2021 – Following a National Advertising Division (NAD) challenge, brought as part of NAD’s routine monitoring of national advertising for truth and transparency, the advertiser ChromaDex, Inc. permanently discontinued advertising claims regarding the performance benefits of its...

Read the Decision
Decision

DSSRC Refers Earnings and Health-Related Product Performance Claims for Q Sciences to FTC and Utah Attorney General

McLean, VA – September 28, 2021 – The Direct Selling Self-Regulatory Council (DSSRC) of BBB National Programs referred certain earnings and representative product performance claims to the Federal Trade Commission (FTC) and Utah Attorney General’s Office for possible enforcement action after Q Sciences, a direct selling...

Read the Decision